<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327741</url>
  </required_header>
  <id_info>
    <org_study_id>90-2348</org_study_id>
    <nct_id>NCT02327741</nct_id>
  </id_info>
  <brief_title>Efficacy of Long Term Plavix Therapy Post Angioplasty</brief_title>
  <official_title>Evaluation of Safety, Benefits and Complications of Long-term Dual Antiplatelet Therapy in Patients With Angioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baqiyatallah university of medical sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1010 patients post stenting were enrolled to receive Plavix more than 12 months and less than
      that and rate of bleeding, complication and major cardiovascular adverse events ( MACE) were
      compared to evaluate safety and feasibility of long term Plavix therapy post stenting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1010 patients from registry of angioplasty and stenting in Shiraz and Baghiatolah hospital
      were enrolled and long term Plavix therapy more than and less than 12 months were compared
      between two groups of patients prospectively and rate of major adverse cardiovascular events
      ( MACE) (death, myocardial infarction, cerebrovascular accidents and revascularization) and
      rate of bleeding were compared between 2 groups.Syntax score and American heart association (
      AHA) score of coronary involvement were measured and MACE was compared to these scores.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Major Bleeding Need Transfusion</measure>
    <time_frame>12 months</time_frame>
    <description>number of patients with major bleeding need transfusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Myocardial Infarction Need Hospital Admission</measure>
    <time_frame>12 month</time_frame>
    <description>The number of patients with myocardial infarction need hospital admission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Central Vascular Accidents Proved by CT Scan</measure>
    <time_frame>12 months</time_frame>
    <description>the number of patients with major vascular brain accidents ( CVA) proved by CT scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Death Due to Cardiac Causes</measure>
    <time_frame>12 months</time_frame>
    <description>the number patients with death due to cardiac causes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Revascularization - Need for Redo Bypass Surgery and Redo Angioplasty</measure>
    <time_frame>12 months</time_frame>
    <description>need for redo bypass surgery and redo angioplasty</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Minor Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>the number of patients with petechiae and superficial ecchymosis or nose bleeding need no admission or drug changes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability - the Number of Patients , Who Are Able to Take Plavix Concerning Compliance and Economic Issues</measure>
    <time_frame>12 months</time_frame>
    <description>the number of patients who are able to take plavix concerning compliance and economic issues</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1010</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>plavix long term</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>taking plavix more than 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>plavix short term</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>taking plavix less than 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>plavix</intervention_name>
    <description>taking plavix more than 12 months</description>
    <arm_group_label>plavix long term</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>plavix</intervention_name>
    <description>taking plavix less than 12 months</description>
    <arm_group_label>plavix short term</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  post stent ( lesion more than 70% and vessel more than 2.25 mm )

        Exclusion Criteria:

          -  allergy to acetylsalicylic acid or clopidogrel,

          -  planned surgery within 24 months of percutaneous coronary intervention unless the dual
             antiplatelet therapy could be maintained throughout the perisurgical period

          -  history of bleeding diathesis

          -  major surgery within 15 days

          -  active bleeding

          -  previous stroke in the past 6 months

          -  concomitant or foreseeable need for oral anticoagulation therapy

          -  pregnancy, life expectancy &lt;24 months, participation in another trial

          -  inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>javad kojuri, M.D. M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>shiraz university of medcal sciences</affiliation>
  </overall_official>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 13, 2014</study_first_submitted>
  <study_first_submitted_qc>December 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <results_first_submitted>March 19, 2020</results_first_submitted>
  <results_first_submitted_qc>April 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 29, 2020</results_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Javad Kojuri</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Dual antiplatelet therapy</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Plavix Short Term</title>
          <description>taking plavix less than 12 months
plavix: taking plavix less than 12 months</description>
        </group>
        <group group_id="P2">
          <title>Plavix Long Term</title>
          <description>taking plavix more than 12 months
plavix: taking plavix more than 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="502"/>
                <participants group_id="P2" count="508"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="502"/>
                <participants group_id="P2" count="508"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Plavix Long Term</title>
          <description>taking plavix more than 12 months
plavix: taking plavix more than 12 months</description>
        </group>
        <group group_id="B2">
          <title>Plavix Short Term</title>
          <description>taking plavix less than 12 months
plavix: taking plavix less than 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="508"/>
            <count group_id="B2" value="502"/>
            <count group_id="B3" value="1010"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="10"/>
                    <measurement group_id="B2" value="60.1" spread="10"/>
                    <measurement group_id="B3" value="60" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="364"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="324"/>
                    <measurement group_id="B2" value="322"/>
                    <measurement group_id="B3" value="646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>type of stents</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>drug eluting stents</title>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                    <measurement group_id="B2" value="327"/>
                    <measurement group_id="B3" value="655"/>
                  </measurement_list>
                </category>
                <category>
                  <title>metallic stents</title>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>coronary risk factors</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="356"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>which coronary vessel involved</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>LAD( left anterior descending)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="392"/>
                    <measurement group_id="B2" value="400"/>
                    <measurement group_id="B3" value="792"/>
                  </measurement_list>
                </category>
                <category>
                  <title>LCX ( left circumflex)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>RCA ( right coronary artery)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Major Bleeding Need Transfusion</title>
        <description>number of patients with major bleeding need transfusion</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plavix Short Term</title>
            <description>taking plavix less than 12 months</description>
          </group>
          <group group_id="O2">
            <title>Plavix Long Term</title>
            <description>taking plavix more than 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Major Bleeding Need Transfusion</title>
          <description>number of patients with major bleeding need transfusion</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Myocardial Infarction Need Hospital Admission</title>
        <description>The number of patients with myocardial infarction need hospital admission</description>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plavix Short Term</title>
            <description>taking plavix less than 12 months</description>
          </group>
          <group group_id="O2">
            <title>Plavix Long Term</title>
            <description>taking plavix more than 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Myocardial Infarction Need Hospital Admission</title>
          <description>The number of patients with myocardial infarction need hospital admission</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Central Vascular Accidents Proved by CT Scan</title>
        <description>the number of patients with major vascular brain accidents ( CVA) proved by CT scan</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plavix Short Term</title>
            <description>taking plavix less than 12 months</description>
          </group>
          <group group_id="O2">
            <title>Plavix Long Term</title>
            <description>taking plavix more than 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Central Vascular Accidents Proved by CT Scan</title>
          <description>the number of patients with major vascular brain accidents ( CVA) proved by CT scan</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Death Due to Cardiac Causes</title>
        <description>the number patients with death due to cardiac causes</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plavix Short Term</title>
            <description>taking plavix less than 12 months</description>
          </group>
          <group group_id="O2">
            <title>Plavix Long Term</title>
            <description>taking plavix more than 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Death Due to Cardiac Causes</title>
          <description>the number patients with death due to cardiac causes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Revascularization - Need for Redo Bypass Surgery and Redo Angioplasty</title>
        <description>need for redo bypass surgery and redo angioplasty</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plavix Short Term</title>
            <description>taking plavix less than 12 months</description>
          </group>
          <group group_id="O2">
            <title>Plavix Long Term</title>
            <description>taking plavix more than 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Revascularization - Need for Redo Bypass Surgery and Redo Angioplasty</title>
          <description>need for redo bypass surgery and redo angioplasty</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Minor Bleeding</title>
        <description>the number of patients with petechiae and superficial ecchymosis or nose bleeding need no admission or drug changes</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plavix Short Term</title>
            <description>taking plavix less than 12 months</description>
          </group>
          <group group_id="O2">
            <title>Plavix Long Term</title>
            <description>taking plavix more than 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Minor Bleeding</title>
          <description>the number of patients with petechiae and superficial ecchymosis or nose bleeding need no admission or drug changes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability - the Number of Patients , Who Are Able to Take Plavix Concerning Compliance and Economic Issues</title>
        <description>the number of patients who are able to take plavix concerning compliance and economic issues</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plavix Short Term</title>
            <description>taking plavix less than 12 months</description>
          </group>
          <group group_id="O2">
            <title>Plavix Long Term</title>
            <description>taking plavix more than 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability - the Number of Patients , Who Are Able to Take Plavix Concerning Compliance and Economic Issues</title>
          <description>the number of patients who are able to take plavix concerning compliance and economic issues</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500"/>
                    <measurement group_id="O2" value="506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Plavix Short Term</title>
          <description>taking plavix less than 12 months</description>
        </group>
        <group group_id="E2">
          <title>Plavix Long Term</title>
          <description>taking plavix more than 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="502"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="502"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>bleeding</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="502"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="502"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>minor bleeding</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="502"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor</name_or_title>
      <organization>shiraz university of medical sciences</organization>
      <phone>009836250352</phone>
      <email>kojurij@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

